Energenesis Biomedical

Executive Summary

Energenesis Biomedical Co., Ltd., founded in 2012 in Taipei, Taiwan, is a private biopharmaceutical company focused on developing novel therapeutics for diabetic wound healing, specifically diabetic foot ulcers (DFUs). Its lead candidate, ENERGI‑F703, is a topical small-molecule treatment currently in Phase 2 clinical development. DFU represents a significant unmet need with limited effective therapies, and ENERGI‑F703's proprietary mechanism targets key pathways in wound repair. The company also offers research reagents under the Visual Protein brand, providing additional revenue. With a robust preclinical and early clinical data package, Energenesis is positioned to address a large and growing global diabetic population. The company has raised funding to support Phase 2 trials and is seeking strategic partnerships for further development and commercialization. Its lean operations and focus on a high-value indication make it an attractive candidate for investors in the wound care space.

Upcoming Catalysts (preview)

• Q4 2026Phase 2a Topline Data for ENERGI‑F70350% success
• H1 2027Strategic Partnership or Licensing Deal for Greater China or Global Rights30% success
• Q2 2027Series B or C Financing Round40% success